Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PAX3 | P23760 | 2/20 | 0.36 |
| ▸ | FOXO1 | Q12778 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | HTR1F | P30939 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25431588 | 0.86 | CCNE1 (0.42) | MAPTCDK2ADORA3ADORA1 | |
| SCHEMBL25431739 | 0.85 | TRPV4 (0.31) | TRPV4 | |
| SCHEMBL26051414 | 0.85 | ALDH1A1 (0.36) | LMNAMAPTCDK2NPC1RAB9A | |
| SCHEMBL31594941 | 0.83 | AR (0.35) | — | |
| SCHEMBL31595089 | 0.83 | AR (0.35) | — | |
| SCHEMBL26053111 | 0.82 | — | — | |
| SCHEMBL25433771 | 0.81 | GSK3B (0.33) | — | |
| SCHEMBL26051690 | 0.80 | GRIN2B (0.33) | MAPT | |
| SCHEMBL31594881 | 0.80 | FASN (0.33) | — | |
| SCHEMBL26052638 | 0.80 | TYK2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230152-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-07-17 | — | — | US | claimed |
| US-20250230152-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250171429-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230152-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNT1 | ADCY1 3694/4885LMNA 1300/4885MAPT 146/4885 |
| US-20250171429-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNT1 | ADCY1 3694/4885LMNA 1300/4885MAPT 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.